Activated lymphocytes including cytokine-induced killer cells and methods for preparing the same
Activated lymphocytes, comprising CD8+ CD56+ NKG2D+ cells cultured with anti-CD3 antibody and interleukin-2, address the limitations of existing immunotherapies by enhancing tumor cell killing and proliferation while minimizing side effects, effectively treating diverse cancers.
Patent Information
- Application Number
- CN202080017747.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-12-16
- Filing Date
- 2020-05-04
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2040-05-04
AI Technical Summary
Existing immunotherapy methods for cancer, such as LAK cells and TILs, face challenges with high side effects due to the use of high concentrations of interleukin-2 and insufficient lymphocyte numbers, limiting their therapeutic effectiveness.
Development of activated lymphocytes comprising CD8+ CD56+ NKG2D+ cells, cultured in a medium with anti-CD3 antibody, interleukin-2, and fetal bovine serum, which enhances tumor cell killing ability and proliferation rate without the need for interleukin-2 co-administration.
The activated lymphocytes demonstrate superior tumor cell killing ability and high proliferation rates with minimal side effects, effectively targeting various types of cancer, including pancreatic cancer, gastric cancer, and others, with a high proportion of CD8+ CD56+ NKG2D+ cells.
Smart Images

Figure CN113544262B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to activated lymphocytes including cytokine-induced killer cells and a method for preparing the same. Background Art
[0002] Cancer is caused by the accumulation of various genetic variations and the loss of normal cell regulatory processes. In the process of regulating the occurrence of cancer, the immune system should go through several continuous processes to effectively kill cancer cells. This is called the "cancer immune cycle". In the first process of the cancer immune cycle as the first step, new tumor antigens (neoantigens) produced by tumor occurrence are released and dendritic cells (DC) work to process the antigens. In this process, components such as proinflammatory cytokines are released from dying tumor cells. In the second step, the antigens captured by dendritic cells are labeled in the form of MHC-I and MHC-II molecules, which activate effector T cells to respond to tumor-specific antigens. In the last step, the activated effector T cells move and infiltrate the tumor site, thereby specifically identifying tumor cells and causing their apoptosis. However, the above cancer immune cycle does not work properly in patients with cancer.
[0003] Regarding the role of the immune system in suppressing and promoting the occurrence of cancer, there is "cancer immunoediting" and it is generally divided into three steps. The first step is "clearance", which refers to the detection of the occurrence of tumors and the killing of them together with the activation of innate immunity and acquired (adaptive) immunity. The process is substantially the same as the process of the above-mentioned cancer immune cycle ("CIC"). In addition, the second step is "balance", that is, the tumor survives in the clearance step and acquired immunity prevents tumor proliferation and forms immunogenicity in the tumor at the same time. In this process, the immune system maintains the so-called "functional dormant state" for the residual tumor cells, which is considered to be the longest time-consuming step in the cancer immunoediting process. Finally, the third step is "escape", in which tumor cells avoid the immune system and proliferate. In this step, tumor cells lose antigens but have enhanced resistance to cytotoxic immunity. In addition, the tumor microenvironment is in an immunosuppressive state, and immunosuppressive cytokines such as VEGF and TGF-β are secreted from the tumor. In addition, regulatory T cells secrete interleukin-10 and TGF-β to inhibit the function of tumor-specific T lymphocytes, express negative co-stimulatory molecules (such as PD-1), and consume interleukin-2, thereby inducing the deterioration of the function of CTLs.
[0004] As a method for treating cancer, surgery is the longest-used method from before the 1890s to the present, and since then, radiotherapy, chemotherapy and precision medicine have been developed. In the case of treating cancer by surgical methods, there is a disadvantage that the tumor may not be completely removed due to the limited scope of surgery. When using radiotherapy and chemotherapy to treat cancer, not only cancer cells are affected by toxicity, but normal cells are also affected by toxicity, so they are often accompanied by strong side effects. In the case of precision medicine, the best treatment method is provided by comprehensively analyzing different genomic information, environmental factors and lifestyles for each patient. However, the standard treatment method currently used in this field uses a method derived from the results of a specific group, so there is a disadvantage that the method cannot treat all diseases of different individuals from the genetic and biochemical aspects. Anti-cancer immunotherapy is a method for inducing, enhancing or suppressing the immune system in cancer patients to treat cancer, which is divided into active immunotherapy and passive immunotherapy. Active immunotherapy has the advantage of maintaining the therapeutic effect for a long time although the response is slow. Representative active immunotherapy includes vaccines and immune checkpoint inhibitors. Passive immunotherapy is characterized by rapid response but short duration. Representative passive immunotherapy approaches include tumor infiltrating lymphocytes (TILs), monoclonal antibodies, chimeric antigen receptor (CAR) T cells, and adaptive immunotherapy.
[0005] Acquired immunotherapy is a method of inducing differentiation and proliferation through a culture process, which can enhance anti-cancer activity in vitro after collecting blood from the patient and isolating only immune cells and injecting the activated immune cells back into the patient, thereby improving the anti-cancer effect. Lymphokine-activated killer cells (LAK cells) with enhanced cytotoxic activity are obtained by culturing monocytes isolated from the peripheral blood of cancer patients in the presence of interleukin-2, and then, they are used to try to treat cancer patients. Tumor infiltrating lymphocytes (TILs) present in the cancer tissue of cancer patients are isolated and cultured in the same manner and used to treat cancer patients.
[0006] However, because these existing immunotherapy methods use high concentrations of interleukin-2, side effects occur and it is difficult to ensure a sufficient number of lymphocytes to produce a therapeutic effect.
[0007] Therefore, the present inventors developed an anti-cancer immune cell therapeutic composition, which has superior tumor cell killing ability and high proliferation rate compared to LAK cells and does not have serious side effects without the need for co-administration of interleukin-2. Therefore, the present invention was completed based on the above development. Summary of the invention
[0008] Problem that the invention aims to solve
[0009] An object of the present invention is to provide activated lymphocytes including cytokine-induced killer cells having high tumor cell killing ability and proliferation rate.
[0010] Furthermore, another object of the present invention is to provide activated lymphocytes including cytokine-induced killer cells having very little side effects.
[0011] Furthermore, another object of the present invention is to provide activated lymphocytes comprising the above-mentioned activated lymphocytes.
[0012] Solutions for solving problems
[0013] 1. An activated lymphocyte comprising CD8 + CD56 + NKG2D + cell.
[0014] 2. The activated lymphocyte according to 1 above, wherein CD8 + CD56 + NKG2D + The proportion of cells is more than 20%.
[0015] 3. The activated lymphocyte according to item 1 above, wherein CD8 + CD56 + NKG2D + The proportion of cells is 20% to 30%.
[0016] 4. An anti-cancer immune cell therapeutic composition comprising the activated lymphocytes according to any one of 1 to 3 above.
[0017] 5. The composition according to 4 above, wherein the cancer is at least one selected from the group consisting of pancreatic cancer, gastric cancer, breast cancer, malignant lung neoplasm, ovarian cancer, brain neoplasm, bile duct cancer, colorectal cancer, gallbladder cancer, rectal cancer, malignant melanoma, cervical cancer, cholangiocarcinoma, colon cancer, metastatic gastric cancer, malignant glioma, renal cancer, duodenal neoplasm, salivary gland neoplasm, esophageal cancer, endometrial cancer, sinus cancer, small intestine cancer, Ewing's sarcoma, uterine sarcoma, malignant neoplasm of Barter's bulge, prostate cancer, prostate neoplasm, osteosarcoma, glioblastoma multiforme polymorph), astrocytoma, uterine cancer, thymoma, endocrine neoplasm, soft tissue cancer, brain stem glioma, recurrent ovarian cancer, tongue neoplasm, liposarcoma, neurofibroma, neuroendocrine cancer, bladder cancer, malignant neoplasm, lymphoma, neuroendocrine cancer of the skin, adrenal cancer, rhabdomyosarcoma, neoplasm, uterine leiomyoma, metastatic breast cancer, liver cancer, colorectal cancer, and signet ring cell carcinoma.
[0018] 6. The composition according to 4 above, wherein the cancer is at least one selected from the group consisting of liver cancer, kidney cancer, pancreatic cancer, malignant melanoma, prostate cancer and colorectal cancer.
[0019] 7. A method for preparing a CD8 + CD56 + NKG2D + A method for activating lymphocytes of cells, the method comprising: culturing lymphocytes separated from peripheral blood in a culture medium containing an anti-CD3 antibody, interleukin-2 and fetal bovine serum (FBS).
[0020] 8. The method according to item 7 above, which does not include a cell sorting step.
[0021] 9. The method according to item 7 above, wherein the culturing is performed in two or more steps, wherein the culture medium in the first step contains anti-CD3 antibody, interleukin-2 and FBS, and the culture medium in the second step contains interleukin-2 and FBS.
[0022] 10. The method according to item 7 above, wherein the culture medium does not contain IFN-γ (interferon-γ), and the activated lymphocytes contain more than 20% CD8 + CD56 + NKG2D + cell.
[0023] 11. The method according to item 9 above, wherein the concentration of the anti-CD3 antibody is 1 to 10 μg / ml, the concentration of interleukin-2 in the culture medium in the first step and the second step is 100 to 800 U / ml, and the concentration of FBS is 0.1 to 15% by volume.
[0024] 12. The method according to item 7 above, wherein the culture is carried out in three steps,
[0025] wherein the culture medium in the first step comprises anti-CD3 antibody, interleukin-2 and FBS, and the culture medium in the second step and the third step comprises interleukin-2 and FBS but does not comprise anti-CD3 antibody, and
[0026] wherein the concentration of the anti-CD3 antibody is 1 to 10 μg / ml, the concentration of interleukin-2 in the culture medium in each of the first step, the second step, and the third step is 100 to 800 U / ml, and the concentration of FBS in the culture medium in the first step is 5 to 15% by volume, the concentration of FBS in the culture medium in the second step is 0.1 to 1% by volume, and the concentration of FBS in the culture medium in the third step is 0.1 to 2% by volume.
[0027] 13. A pharmaceutical composition for preventing or treating cancer, comprising the activated lymphocyte according to any one of 1 to 3 above.
[0028] 14. The composition according to item 13 above, wherein the cancer is at least one selected from the group consisting of pancreatic cancer, gastric cancer, breast cancer, malignant lung neoplasms, ovarian cancer, brain neoplasms, biliary tract cancer, colorectal cancer, gallbladder cancer, rectal cancer, malignant melanoma, cervical cancer, bile duct cancer, colon cancer, metastatic gastric cancer, malignant glioma, renal cancer, duodenal neoplasms, salivary gland neoplasms, esophageal cancer, endometrial cancer, sinus cancer, small intestinal cancer, Ewing's sarcoma, uterine sarcoma, Vater's Malignant neoplasms of the ampullary ampulla, prostate cancer, prostatic neoplasms, osteosarcoma, malignant glioma multiforme, astrocytoma, uterine cancer, thymoma, endocrine gland neoplasms, soft tissue cancer, brain stem glioma, recurrent ovarian cancer, tongue neoplasms, liposarcoma, neurofibroma, neuroendocrine cancer, bladder cancer, malignant neoplasms, lymphoma, neuroendocrine cancer of the skin, adrenal cancer, rhabdomyosarcoma, neoplasms, uterine leiomyoma, metastatic breast cancer, liver cancer, colorectal cancer, and signet ring cell carcinoma.
[0029] 15. The composition according to 13 above, wherein the cancer is at least one selected from the group consisting of liver cancer, kidney cancer, pancreatic cancer, malignant melanoma, prostate cancer and colorectal cancer.
[0030] 16. The composition according to 13 above, wherein the composition comprises activated lymphocytes, saline and human serum albumin.
[0031] Effects of the Invention
[0032] The activated lymphocytes of the present invention may include CD8 + CD56 + NKG2D + cells to show excellent anticancer activity.
[0033] The activated lymphocytes of the present invention may have a very high proportion of CD8 + CD56 + NKG2D + cells to maximize anticancer activity.
[0034] The preparation method of the present invention can produce CD8 + CD56 + NKG2D + Activated lymphocytes. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 These are images showing the cell phenotypes of activated lymphocytes confirmed by FACS analysis.
[0036] Figure 2 The graphs show the results of a study on the anticancer effect of activated lymphocytes on human renal carcinoma (ACHN).
[0037] Figure 3 The graphs show the results of a study on the anticancer effect of activated lymphocytes on human pancreatic cancer (AsPC-1).
[0038] Figure 4 The graphs show the results of a study on the anticancer effect of activated lymphocytes on human melanoma cancer (LOX-IMV1).
[0039] Figure 5 The graphs show the results of a study on the anticancer effect of activated lymphocytes on human prostate cancer (PC-3).
[0040] Figure 6 The images show the results of a study on the anticancer effect of activated lymphocytes on human prostate cancer (PC-3).
[0041] Figure 7 The graphs show the results of a study on the anticancer effect of activated lymphocytes on human colon cancer (SW620).
[0042] Figure 8The figure shows the results of a clinical trial on activated lymphocytes for liver cancer.
[0043] Fig. 9 This figure shows the long-term follow-up results of a clinical trial targeting activated lymphocytes for liver cancer.
[0044] Fig.10 The figure shows the results of a clinical trial targeting activated lymphocytes for malignant glioma.
[0045] Fig.11 The figure shows the results of a clinical trial on pancreatic cancer using activated lymphocytes. DETAILED DESCRIPTION
[0046] Hereinafter, the present invention will be described in detail.
[0047] The present invention relates to activated lymphocytes.
[0048] As used herein, activated lymphocytes are immune effector cell populations, in particular, lymphocytes comprising CD3 + CD56 + Cells, CD8 + CD56 + Cells and CD3 + CD8 + Heterogeneous cell populations such as cells.
[0049] The activated lymphocytes of the present invention may include CD8 + CD56 + NKG2D + cell.
[0050] When including CD8 + CD56 + NKG2D + cells, it can show excellent anti-cancer effects.
[0051] CD8 + CD56 + NKG2D + The proportion of cells may be, for example, 20% or more, specifically 20% to 30%, and more specifically 25% to 30%, but is not limited thereto. + CD56 + NKG2D + cells, the anti-cancer effect can be maximized.
[0052] The activated lymphocytes of the present invention may include cells having several phenotypes, such as CD3 + CD56 + 、CD8 + CD56 + and CD3+ CD8 + wait.
[0053] In particular, in the activated lymphocytes of the present invention, CD3 + CD56 + The ratio of the cells may be, for example, 40% or more, specifically 40% to 60%, and more specifically 40% to 50%, but is not limited thereto.
[0054] CD8 + CD56 + The ratio of the cells may be, for example, 30% or more, specifically 30% to 40%, and more specifically 30% to 35%, but is not limited thereto.
[0055] CD3 + CD8 + The ratio of the cells may be, for example, 60% or more, specifically 60% to 90%, and more specifically 60% to 70%, but is not limited thereto.
[0056] The activated lymphocytes of the present invention can be obtained by activating, proliferating and culturing lymphocytes separated from peripheral blood. Specifically, the activated lymphocytes can be obtained by culturing lymphocytes separated from peripheral blood in a culture medium containing anti-CD3 antibodies, interleukin-2 and FBS, but are not limited thereto.
[0057] Furthermore, the present invention relates to an anti-cancer immune cell therapeutic composition comprising the above-mentioned activated lymphocytes.
[0058] In the present invention, the immune cell therapeutic agent is a type of anti-cancer immune cell therapeutic agent that treats cancer by proliferating and activating a large number of immune cells present in human blood in vitro and then administering the activated immune cells back to the human body. It is a personalized anti-cancer therapeutic agent that activates the patient's own immune cells to induce immunity in vivo, such as an anti-cancer immune cell therapeutic agent using dendritic cells.
[0059] The composition of the present invention may include the above-mentioned activated lymphocytes, thereby showing an excellent anti-cancer effect.
[0060] Cancers to be prevented or treated with the composition of the present invention may include, for example, pancreatic cancer, gastric cancer, breast cancer, malignant lung neoplasms, ovarian cancer, brain neoplasms, biliary tract cancer, colorectal cancer, gallbladder cancer, rectal cancer, malignant melanoma, cervical cancer, bile duct cancer, colon cancer, metastatic gastric cancer, malignant glioma, renal cancer, duodenal neoplasms, salivary gland neoplasms, esophageal cancer, endometrial cancer, sinus cancer, small intestine cancer, Ewing's sarcoma, uterine sarcoma, malignant neoplasms of the ampulla of Vater, anterior prostate cancer, prostate neoplasms, osteosarcoma, glioblastoma multiforme, astrocytoma, uterine cancer, thymoma, endocrine gland neoplasms, soft tissue cancer, brain stem glioma, recurrent ovarian cancer, tongue neoplasms, liposarcoma, neurofibroma, neuroendocrine cancer, bladder cancer, malignant neoplasms, lymphoma, cutaneous neuroendocrine cancer, adrenal cancer, rhabdomyosarcoma, neoplasms, uterine leiomyoma, metastatic breast cancer, liver cancer, colorectal cancer, and signet ring cell carcinoma, but are not limited thereto.
[0061] The composition of the present invention can be formulated and used according to conventional methods in the following dosage forms: oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols; external preparations; suppositories; and sterile injection solutions.
[0062] The carrier, excipient and diluent that may be included in the composition of the present invention can include for example, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talcum, magnesium stearate and mineral oil. When preparing the composition, the commonly used diluent or excipient in this area such as filler, extender (extender), adhesive, wetting agent, disintegrant and surfactant can be used to prepare the preparation. The solid preparation for oral administration can include tablets, pills, powders, granules, capsules etc., and can be produced by mixing the above-mentioned compounds with at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin etc. This type of solid preparation. In addition, except simple excipients, lubricants such as magnesium stearate and talcum can also be used. Liquid preparations for oral administration can include suspensions, liquid solutions, emulsions, syrups, etc. Except water and liquid paraffin that are usually used as simple diluents, various excipients such as wetting agents, sweeteners, essences and preservatives can also be included. Meanwhile, preparations for parenteral administration can include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories. As non-aqueous solvents and suspensions, propylene glycol, polyethylene glycol, vegetable oils such as olive oil and injectable esters such as ethyl oleate can be used. As the matrix for suppositories, witepsol, polyethylene glycol, Tween 61, cocoa butter, laurin and glycerin gelatin, etc. can be used.
[0063] The amount of the composition of the present invention may vary depending on the age, sex and weight of the patient. However, for example, a composition containing 1×10 9 Up to 2×10 10 The dosage may be, for example, 100 to 1,000 ml, and specifically 100 to 300 ml. In addition, the dosage may be increased or decreased depending on the administration route, degree of disease, sex, weight, age, etc. of the patient. Therefore, the dosage does not limit the scope of the present invention in any way.
[0064] In addition, the present invention relates to a method for preparing a method comprising CD8 + CD56 + NKG2D + Cell activation lymphocyte method.
[0065] The method of the present invention may include culturing lymphocytes isolated from peripheral blood in a culture medium comprising an anti-CD3 antibody, interleukin-2, and FBS.
[0066] The peripheral blood may be autologous peripheral blood.
[0067] If necessary, peripheral blood is centrifuged to remove the upper plasma layer and lymphocytes can be obtained from the separated mononuclear cell layer.
[0068] Lymphocytes can be cultured in a medium containing an anti-CD3 antibody, interleukin-2, and FBS, thereby activating and proliferating the lymphocytes.
[0069] The concentration of the anti-CD3 antibody is not particularly limited, and may be, for example, 0.1 to 100 μg / ml, and specifically 1 to 10 μg / ml.
[0070] The anti-CD3 antibody may be provided by administering it to a culture flask, but is not limited thereto.
[0071] The concentration of interleukin-2 is not particularly limited, and may be, for example, 50 to 1000 U / ml, and specifically 100 to 800 U / ml. Within the above range, 100 to 800 U / ml, 400 to 800 U / ml, 100 to 500 U / ml, 100 to 300 U / ml, etc. may be variously included.
[0072] The concentration of FBS is not particularly limited, and may be, for example, 0.1 to 15% by volume ("vol %").
[0073] The culture medium of the present invention may not contain interferon gamma (IFN-γ).
[0074] The culture medium according to the present invention may further include components generally used for lymphocyte culture, T cell activation, colony proliferation and long-term culture. For example, the culture medium may contain glycine, L-arginine, L-asparagine, L-aspartic acid, L-cystine 2HCl, L-glutamic acid, L-glutamine, L-histidine, L-hydroxyproline, L-isoleucine, L-leucine, L-lysine hydrochloride, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine disodium salt dihydrate, L-valine, biotin, choline chloride, D-calcium pantothenate, folic acid, nicotinamide, p-aminobenzoic acid, pyridoxine hydrochloride, riboflavin, thiamine hydrochloride, vitamin B12, i-inositol, calcium nitrate, magnesium sulfate, potassium chloride, sodium bicarbonate, sodium chloride, disodium hydrogen phosphate anhydrous, D-glucose, glutathione, HEPES, and phenol red, etc., but are not limited thereto.
[0075] An example of a commercially available product may be RPMI 1640 medium from GIBCO, but is not limited thereto.
[0076] If necessary, the culture can be carried out in several steps. For example, the culture can be carried out in one step or in two or more steps.
[0077] When culturing is performed in two or more steps, for example, lymphocytes cultured in step 1 may be separated and cultured in step 2 by transferring them to a new culture medium.
[0078] When culturing is performed in two or more steps, the first-step culture medium may contain anti-CD3 antibodies, interleukin-2, and FBS, and the second-step culture medium may contain interleukin-2 and FBS. More specifically, the first-step culture medium may contain anti-CD3 antibodies and interleukin-2, and the second-step culture medium may contain interleukin-2 and FBS, but may not contain anti-CD3 antibodies.
[0079] The anti-CD3 antibody and interleukin-2 may be contained at concentrations within the above ranges, respectively, and the culture medium exemplified above may be used.
[0080] When culturing is performed in two or more steps, the first step culture medium may contain 5 to 15 volume % FBS, and specifically 8 to 12 volume % FBS, and the second step culture medium may contain 0.1 to 2 volume % FBS, and specifically 0.3 to 1.5 volume % FBS, but is not limited thereto.
[0081] When culturing is performed in three steps, the culture medium in step 1 may contain 5 to 15 volume % FBS, and specifically 8 to 12 volume % FBS, the culture medium in step 2 may contain 0.1 to 1 volume % FBS, and specifically 0.3 to 0.8 volume % FBS, and the culture medium in step 3 may contain 0.1 to 2 volume % FBS, and specifically 0.5 to 1.5 volume % FBS, but are not limited thereto.
[0082] The cells may be cultured in a common cell culture method, for example, in a CO2 incubator. The CO2 concentration may be, for example, 1% to 10%, and specifically 3% to 7%, and the temperature may be 30°C to 40°C, and specifically 35°C to 38°C, but is not limited thereto.
[0083] The culture may be performed until the lymphocytes are sufficiently activated and proliferated, and may be performed for, for example, 10 to 30 days, and specifically 12 to 21 days, but is not limited thereto.
[0084] In order to improve the culture efficiency, it is preferred to add the medium according to the increase in the number of cells during the culture period. The medium may be added in a cycle of, for example, once every 1 to 10 days, and specifically once every 1 to 7 days, to prevent the deterioration of the medium, but is not limited thereto.
[0085] Then, if necessary, the culture medium may be centrifuged to remove the supernatant, thereby isolating the activated lymphocytes.
[0086] The amount of the culture period and culture medium exemplified above can be appropriately adjusted according to the growth rate and growth degree of the cells. Specifically, since the rate of cell growth depends on the donor of the cells, the culture period can be appropriately determined within the above range. In addition, culture medium can be further added or the cells can be transferred to a large amount of culture medium.
[0087] In the methods of the present invention, lymphocytes may be isolated from peripheral blood and frozen.
[0088] Specifically, lymphocytes can be isolated from peripheral blood and frozen after culture. The culture can be performed in the above-mentioned culture medium.
[0089] Frozen lymphocytes can be thawed and then cultured again to obtain activated lymphocytes.
[0090] The lymphocytes may be thawed by heating at 30°C to 40°C for 1 minute to 20 minutes, but are not limited thereto.
[0091] Thawed lymphocytes can be cultured in medium containing anti-CD3 antibody, interleukin-2, and FBS.
[0092] The concentrations of the anti-CD3 antibody, interleukin-2, and FBS may be within the above ranges, and the above components may be used as medium components, but are not limited thereto.
[0093] Specifically, the culturing of thawed lymphocytes may be performed in a single step or divided into two or more steps, and more specifically, the culturing may be performed in three or more steps.
[0094] When culturing is performed in two steps, for example, after the first culture in a medium not containing an anti-CD3 antibody, the second culture in a medium containing an anti-CD3 antibody may be performed.
[0095] The first culture may be performed for, for example, 1 to 3 days, and the second culture may be performed for, for example, 2 to 5 days, but are not limited thereto.
[0096] The concentration of the anti-CD3 antibody may be within the above range.
[0097] The medium of the third culture may not contain anti-CD3 antibodies.
[0098] In the third culture medium, FBS may be included in an amount of, for example, 0.1 to 2 volume %, and specifically 0.5 to 1.5 volume %, but is not limited thereto.
[0099] The method of the present invention may include the above-exemplified steps, thereby separating CD3 T cells even without a separate cell sorting process (e.g., fluorescence activated cell sorting (FACS), magnetic activated cell sorting (MACS), etc.). + 、CD8 + 、CD56 + or NKG2D + Cells with high CD8 + CD56 + NKG2D + Cell ratio of activated lymphocytes.
[0100] Furthermore, the present invention relates to a pharmaceutical composition for preventing or treating cancer, which comprises activated lymphocytes.
[0101] The type of cancer is not particularly limited and may be at least one selected from the group consisting of, for example, pancreatic cancer, gastric cancer, breast cancer, malignant lung neoplasm, ovarian cancer, brain neoplasm, biliary tract cancer, colorectal cancer, gallbladder cancer, rectal cancer, malignant melanoma, cervical cancer, bile duct cancer, colon cancer, metastatic gastric cancer, malignant glioma, renal cancer, duodenal neoplasm, salivary gland neoplasm, esophageal cancer, endometrial cancer, sinus cancer, small intestine cancer, Ewing's sarcoma, uterine sarcoma, pot of Vater's disease The present invention relates to a malignant neoplasm of the abdomen, prostate cancer, prostate neoplasm, osteosarcoma, malignant glioma multiforme, astrocytoma, uterine cancer, thymoma, endocrine neoplasm, soft tissue cancer, brain stem glioma, recurrent ovarian cancer, tongue neoplasm, liposarcoma, neurofibroma, neuroendocrine cancer, bladder cancer, malignant neoplasm, lymphoma, neuroendocrine cancer of the skin, adrenal cancer, rhabdomyosarcoma, neoplasm, uterine leiomyoma, metastatic breast cancer, liver cancer, colon cancer and signet ring cell carcinoma. Specifically, the cancer described herein can be at least one selected from the group consisting of liver cancer, kidney cancer, pancreatic cancer, malignant melanoma, prostate cancer and colorectal cancer, but is not limited thereto.
[0102] The composition may include various carriers, excipients, diluents, etc. as exemplified above. According to one embodiment, saline may be included, specifically, activated lymphocytes, saline, and human serum albumin may be included, and more specifically, the composition may consist of the above components alone.
[0103] Human serum albumin may be provided in a state of being contained in saline, and specifically 0.5% to 3% and more specifically 1% human serum albumin may be used, but is not limited thereto.
[0104] Hereinafter, the present invention will be described and illustrated in detail with the help of the following examples.
[0105] Example
[0106] Preparation of activated lymphocytes
[0107] 1. Preparation method 1
[0108] (1) Blood collection and lymphocyte separation
[0109] The production of activated lymphocytes for use in the present invention can be started by collecting 20-70 mL of autologous peripheral blood from a patient. The collected blood is transferred to a 250 mL test tube and diluted 3 times with RPMI1640 at a ratio of 1:2, then 30-40 mL of the diluted blood is dispensed into a 50 mL test tube in which Ficoll-paque is dispensed without mixing the layers together, and the test tube is centrifuged at a rotation speed of 2,000 rpm at room temperature for 20 minutes.
[0110] After slowly removing the upper plasma layer to prevent the cells of the lymphocyte layer from being aspirated, the separated mononuclear cell layer was transferred to a 50 mL test tube. The separated mononuclear cell layer was diluted 3 times with RPMI1640 at a ratio of 1:2, centrifuged at room temperature at a rotation speed of 2,000 rpm for 5 minutes, and then the supernatant was removed while releasing the collected cells.
[0111] (2) Lymphocyte culture 1
[0112] The lymphocytes separated in (1) above were released into 50 mL of lymphocyte culture medium (lymphomedium), and 1 μg / ml to 10 μg / ml of anti-CD3 antibody were dispensed into a coating having a bottom area of 225 cm 2The cells were placed in a culture flask and then cultured in a cell culture incubator at 37°C and 5% CO2. At this time, 500 to 800 U / ml of interleukin-2 and 10% FBS were included in the lymphocyte culture medium.The lymphocyte culture medium further comprises components commonly used for suspending cell cultures such as various mammalian cells including human leukemia cells, that is, the lymphocyte culture medium may be a culture medium comprising, for example, calcium nitrate (Ca(NO3)2 4H2O, 90 to 100 mg / L), potassium chloride (KCl, 380 to 400 mg / L), magnesium sulfate (MgSO4, 40 to 50 mg / L), sodium chloride (NaCl, 5500 to 6000 mg / L), disodium hydrogen phosphate (Na2HPO4, 750 to 800 mg / L), D-glucose (1900 to 2000 mg / L), glutathione (0.8 to 1.5 mg / L), phenol red (4 to 6 mg / L), L-arginine (190 to 200 mg / L), L-asparagine (40 to 50 mg / L), L-aspartic acid (15 to 25 mg / L), L- Cystine dihydrochloride (L-cystine 2HCL, 50 to 70 mg / L), L-glutamic acid (15 to 25 mg / L), L-glutamine (450 to 460 mg / L), glycine (8 to 15 mg / L), L-histidine (10 to 20 mg / L), L-hydroxyproline (15 to 25 mg / L), L-isoleucine (45 to 55 mg / L), L-leucine (45 to 55 mg / L), L-lysine hydrochloride (L-lysine HCL, 30 to 50 mg / L), L-methionine (10 to 20 mg / L), L-phenylalanine (10 to 20 mg / L), L-proline 2-aminobenzoic acid (0.5-1.5mg / L), L-aminobenzoic acid (0.5-1.5mg / L), L-phosphorylation (10-25mg / L), L-serine (25-35mg / L), L-threonine (15-25mg / L), L-tryptophan (1-10mg / L), L-tyrosine 2Na2H2O (25-35mg / L), L-valine (15-25mg / L), biotin (0.1-1mg / L), D-pantothenate calcium (0.1-1mg / L), choline chloride (1-5mg / L), folic acid (0.5-1.5mg / L), I-inositol (30-40mg / L), nicotinamide (0.5-1.5mg / L), p-aminobenzoic acid (0.5-1 .5 mg / L), pyridoxine hydrochloride (pyridoxine HCL, 0.5 to 1.5 mg / L), riboflavin (0.1 to 1 mg / L), thiamine hydrochloride (thiamine HCL, 0.1 to 1.5 mg / L), vitamin B12 (0.001 to 0.01 mg / L), oxaloacetate (0.1 to 1 g / L), insulin (0.001 to 0.01 g / L), kanamycin (0.01 to 0.1 g / L), streptomycin (0.01 to 0.1 g / L), HEPES (1 to 5 g / L), sodium bicarbonate (NaHCO3, 1 to 5 g / L), and sodium pyruvate (100 to 150 mg / L).
[0113] On the 3rd to 4th day of culture, the culture flask in culture was taken out to visually inspect the cells under a microscope, and then a total of 200 mL of lymphocyte culture medium was added according to the increase in cell concentration, and it was cultured in a cell culture incubator at 37°C and 5% CO2.
[0114] (3) Lymphocyte culture 2
[0115] On the 5th to 8th day of cultivation, the culture flask in the culture was taken out and the cells attached to the bottom were removed by patting the side of the culture flask with hands. A bagpack containing 750mL bagpack medium was prepared and 3.75mL FBS was added thereto until the final concentration of FBS reached 0.5 volume%. The syringe port of the bag was opened and disinfected with 70% ethanol, and then the syringe port was connected to a 60mL lock type syringe. After the cells cultured in the culture flask were transferred together with the culture medium using a syringe, the bag and the syringe were separated. Then, closed culture was carried out at 37°C, 5% CO2 in a cell culture incubator for the bag. The bag culture medium contained 100 to 300U / ml of interleukin-2.
[0116] The bag culture medium further comprises some components commonly used for colony proliferation and T cell proliferation, specifically, a culture medium comprising calcium chloride (CaCl2, 50 to 60 mg / L), copper sulfate-5H2O (CuSO4-H2O, 0.0001 to 0.001 mg / L), iron nitrate 9H2O (Fe(NO3)3·9H2O, 0.1 to 1 mg / L), ferrous sulfate-7H2O (FeSO4-7H2O, 0.1 to 0.5 mg / L), potassium chloride (KCl, 140 to 160 mg / L), magnesium chloride (MgCl2, 10 to 20 mg / L), magnesium sulfate (MgSO4, 20 to 30 mg / L ), sodium chloride (NaCl, 3000 to 4000 mg / L), sodium hydrogen phosphate (NaH3PO4, 20 to 40 mg / L), disodium hydrogen phosphate (Na2HPO4, 20 to 40 mg / L), zinc sulfate-7H2O (ZnSO4-7H2O, 0.1 to 1 mg / L), D-glucose (1500 to 1600 mg / L), hypoxanthine sodium (1 to 5 mg / L), linoleic acid (0.01 to 0.1 mg / L), lipoic acid (0.01 to 0.1 mg / L), phenol red (1 to 10 mg / L), putrescine dihydrochloride (putrescine 2HCl, 0.01 to 0.1 mg / L), sodium pyruvate (50 to 60 mg / L), thymidine (0.1 to 0.5 mg / L), L-alanine (1 to 5 mg / L), L-arginine hydrochloride (L-arginine-HCl, 70 to 80 mg / L), L-asparagine-H2O (1 to 5 mg / L), L-aspartic acid (1 to 5 mg / L), L-cysteine-H2O (5 to 10 mg / L), L-cysteine dihydrochloride (L-cystine 2HCL, 10 to 20 mg / L), L-glutamic acid (1 to 5 mg / L), L-glutamine (280 to 290 mg / L), glycine (5 to 15 mg / L), L-histidine hydrochloride-H2O (L-histidine HCL-H2O , 10 to 20 mg / L), L-isoleucine (20 to 30 mg / L), L-leucine (25 to 35 mg / L), L-lysine hydrochloride (L-lysine HCl, 40 to 50 mg / L), L-methionine (5 to 10 mg / L), L-phenylalanine (15 to 20 mg / L), L-proline (5 to 10 mg / L), L-serine (10 to 15 mg / L), L-threonine (20 to 30 mg / L), L-tryptophan (1 to 10 mg / L), L-tyrosine 2Na2H2O (25 to 30 mg / L), L-valine (20 to 30 mg / L), biotin (0.001 to 0.01mg / L), D-pantothenate calcium (D-pantothenate Ca, 1 to 5mg / L), choline chloride (1 to 10mg / L), folic acid (1 to 5mg / L), I-inositol (1 to 10mg / L), niacinamide (1 to 5mg / L), pyridoxine hydrochloride (pyridoxine HCL, 1 to 5mg / L), riboflavin (0.1 to 0.5mg / L), thiamine hydrochloride (thiamine HCL, 1 to 5mg / L), vitamin B12 (0.1 to 0.5mg / L), g / L), oxaloacetate (0.1 to 0.5 g / L), insulin (0.001 to 0.01 g / L), kanamycin (0.01 to 0.1 g / L), streptomycin (0.01 to 0.1 g / L), HEPES (1 to 5 g / L), sodium bicarbonate (NaHCO3, 0.1 to 1 g / L), albumin (0.1 to 1 g / L), selenium (0.001 to 0.01 g / L), and AIM-V (400 to 600 mL).
[0117] (4) Lymphocyte culture 3
[0118] After culturing in the bag for 3 to 8 days, a split bag containing 1,000 mL of split medium was prepared and 10 mL of FBS was added thereto through a syringe port until the concentration of FBS reached 1% by volume. The two lines of the separation bag and the bag containing the cells in culture were joined using a sterile connection device. After placing the full amount of the separation medium of the separation bag into the bag containing the cells, the bag was divided equally so that the same amount of the contents of the bag entered each culture container, and then the two separate bags were joined separately using a sterile adhesive. Thereafter, closed culture was performed in a cell culture incubator at 37° C., 5% CO2 for more than 3 days. The separation medium contained 100 to 300 U / ml of interleukin-2.
[0119] The separation medium further comprises some components commonly used for colony proliferation and long-term culture, specifically, a medium comprising calcium chloride (CaCl2, 100 to 120 mg / L), copper sulfate-5H2O (CuSO4-5H2O, 0.001 to 0.01 mg / L), ferric nitrate 9H2O (Fe(NO3)3·9H2O, 0.01 to 0.1 mg / L), ferrous sulfate-7H2O (FeSO4-7H2O, 0.1 to 1 mg / L), potassium chloride (KCl, 300 to 320 mg / L), magnesium chloride (MgCl2, 25 to 30 mg / L), magnesium sulfate (MgSO4, 45 to 50 mg / L) ), sodium chloride (NaCl, 6500 to 7500 mg / L), sodium hydrogen phosphate (NaH3PO4, 60 to 70 mg / L), disodium hydrogen phosphate (Na2HPO4, 70 to 80 mg / L), zinc sulfate-7H2O (ZnSO4-7H2O, 0.1 to 1 mg / L), D-glucose (3100 to 3200 mg / L), hypoxanthine sodium (1 to 5 mg / L), linoleic acid (0.01 to 0.1 mg / L), lipoic acid (0.1 to 0.5 mg / L), phenol red (5 to 10 mg / L), putrescine dihydrochloride (putrescine 2HCl, 0.01 to 1 mg / L), sodium pyruvate (100 to 120 mg / L), sodium pyruvate (100 to 120 mg / L), sodium iodide (0.01 to 0.1 mg / L), sodium pyruvate (0.01 to 0.5 mg / L), sodium iodide (0.01 to 0.1 mg / L), sodium iodide ...1 mg / L), sodium iodide (0.01 to 0.1 mg / L), sodium iodide (0.01 to 0.1 mg / L), sodium iodide (0.01 to 0.1 mg / L), sodium iodide (0.01 to 0. L), thymidine (0.1 to 1 mg / L), L-alanine (1 to 10 mg / L), L-arginine hydrochloride (L-arginine-HCl, 140 to 160 mg / L), L-asparagine-H2O (5 to 10 mg / L), L-aspartic acid (5 to 10 mg / L), L-cysteine-H2O (15 to 20 mg / L), L-cystine dihydrochloride (L-cystine 2HCl, 30 to 35 mg / L), L-glutamic acid (5 to 10 mg / L), L-glutamine (560 to 570 mg / L), glycine (15 to 20 mg / L), L-histidine hydrochloride-H2O (L-histidine HCL-H2O , 30 to 35 mg / L), L-isoleucine (50 to 60 mg / L), L-leucine (55 to 65 mg / L), L-lysine hydrochloride (L-lysine HCl, 85 to 95 mg / L), L-methionine (15 to 20 mg / L), L-phenylalanine (30 to 40 mg / L), L-proline (15 to 20 mg / L), L-serine (20 to 30 mg / L), L-threonine (50 to 55 mg / L), L-tryptophan (5 to 10 mg / L), L-tyrosine 2Na2H2O (50 to 60 mg / L), L-valine (50 to 55 mg / L), biotin (0.001 to 0.01mg / L), D-pantothenate calcium (D-pantothenate Ca, 1 to 5mg / L), choline chloride (5 to 15mg / L), folic acid (1 to 5mg / L), I-inositol (10 to 15mg / L), niacinamide (1 to 5mg / L), pyridoxine hydrochloride (pyridoxine HCl, 1 to 5mg / L), riboflavin (0.1 to 1mg / L), thiamine hydrochloride (thiamine HCl, 1 to 5mg / L), vitamin B 12 (0.1 to 1 mg / L), oxaloacetate (0.1 to 1 g / L), insulin (0.001 to 0.01 g / L), kanamycin (0.01 to 0.1 g / L), streptomycin (0.01 to 0.1 g / L), HEPES (1 to 5 g / L), sodium bicarbonate (NaHCO3, 1 to 5 g / L), albumin (0.5 to 1.5 g / L), and selenium (0.001 to 0.01 g / L).
[0120] (5) Contamination and performance confirmation
[0121] Prior to harvesting the cells, a sample of the product in culture was taken to confirm product contamination and performance.
[0122] (5)-1: Three days before cell collection, after visual inspection of cells, the culture solution was shaken to evenly mix the cells. First, after sterilizing the syringe port of the bag in which the cells were cultured, 32 to 55 mL of the cell culture solution was taken with a syringe and provided for requesting each test (A to C).
[0123] (5)-2: One day before or on the day of cell collection, after visual inspection of the cells, the culture solution was shaken to evenly mix the cells. First, after sterilizing the syringe port of the bag in which the cells were cultured, 24 to 30 mL of the cell culture solution was taken with a syringe and provided for requesting each test (D and E).
[0124] A: Sterility test
[0125] B: Mycoplasma negative test
[0126] C: Negative test for exogenous viruses
[0127] D: Confirmation test and purity test
[0128] E: Efficacy test
[0129] (6) Cell collection
[0130] The culture was terminated on the 12th to 21st day of culture, and 1,000 mL of the cell culture solution in one bag was transferred to four 250 mL test tubes. At this time, the collection line of the culture bag was sterilized with 70% ethanol and then cut with scissors.
[0131] After collecting the cells by centrifugation at a rotation speed of 2,000 rpm at room temperature for 5 minutes, the supernatant was removed and the cells were well dispersed using a vortex machine. For the remaining culture bags, the cell culture solution was collected into 4 identical test tubes and then centrifuged under the same conditions. The supernatant was removed and the cells were well dispersed.
[0132] After human serum albumin and physiological saline were mixed to prepare a 0.1% human serum albumin solution, the cells in the test tube were first washed.
[0133] After the cells were collected by centrifugation at a rotation speed of 2,000 rpm at room temperature for 5 minutes, the supernatant was completely removed and the cells were dispersed using a vortex machine.
[0134] After washing the cells twice with a 0.1% human serum albumin solution, the solution was centrifuged at a rotation speed of 2,000 rpm at room temperature to collect the cells, the supernatant was removed, and then the cells were dispersed using a vortex machine.
[0135] A 1% human serum albumin solution was prepared by mixing human serum albumin and physiological saline.
[0136] The collected cells were suspended in a 1% human serum albumin solution and then mixed uniformly. A portion of the sample was collected and provided for requesting each test (A to D).
[0137] After the line of the finished filling bag was sterilized with 70% ethanol, the line was cut and connected to a 50 mL syringe, and then the finished filling bag was filled with the cell suspension.
[0138] The line of the finished filling bag was sealed 3 times (0.5 cm) at 1 cm from the inlet, and then the second sealed part was cut to finally complete the activated lymphocytes.
[0139] A: Total cell number measurement test and cell viability test
[0140] B: Sterility test
[0141] C: Endotoxin test
[0142] D: Mycoplasma detection test
[0143] 2. Preparation method 2
[0144] (1) Blood collection and lymphocyte separation
[0145] The production of activated lymphocytes for the present invention is started by collecting 20 to 70 mL of autologous peripheral blood from the patient. The collected blood is transferred to a 250 mL test tube, diluted 3 times at a ratio of 1:2 with RPMI1640, and 30 to 40 mL of the diluted blood is dispensed into a 50 mL test tube in which Ficoll-paque is dispensed without mixing the layers, and then centrifuged at a rotation speed of 2,000 rpm at room temperature for 20 minutes.
[0146] After the upper plasma layer was slowly removed so that the cells of the lymphocyte layer were not absorbed, the separated mononuclear cell layer was transferred to a 50 mL test tube. The separated mononuclear cell layer was diluted 3 times with RPMI1640 at a ratio of 1:2, centrifuged at a rotation speed of 2,000 rpm at room temperature for 5 minutes, and then the supernatant was removed and the collected cells were dispersed.
[0147] (2) Lymphocyte culture
[0148] The lymphocytes separated in (1) above were dispersed in 50 mL of lymphocyte culture medium and dispensed into 225 cm 2 The cells were placed in a culture flask coated with anti-CD3 antibody on the bottom area of 100 μm, and then cultured in a cell culture incubator at 37° C. and 5% CO 2 . At this time, the lymphocyte culture medium contained 500 to 800 U / ml of interleukin-2 and 10% FBS.
[0149] On the 3rd to 4th day of culture, the culture flask in culture was taken out to visually inspect the cells under a microscope, a total of 130 mL of lymphocyte culture medium was added thereto according to the increase in cell concentration, and then cultured in a cell culture incubator at 37°C, 5% CO2.
[0150] (3) Lymphocyte freezing
[0151] On the fifth day of culture, the culture flask in culture was taken out to visually inspect the cells under a microscope to determine whether the cells were suitable. If the cells were suitable by visual inspection, the cells attached to the bottom were removed by tapping the side of the culture flask with the hand. At this time, care should be taken not to generate bubbles. Collect 500 μL of the detached cells, count the number of cells, and then calculate to reach 3×10 per cryovial. 7 10 cells or more to determine how many cryovials are needed. Thereafter, prepare the required cryovials.
[0152] FBS was added to the solution to give a concentration of 10% according to the number of cryovials to prepare a cell cryopreservation solution.
[0153] The cultured lymphocytes in the culture flask are transferred to a 250mL test tube, centrifuged at room temperature for 5 minutes at a rotation speed of 1,200rpm, and then the supernatant is removed by suction. At this time, care should be taken not to include cells in the supernatant. After patting the cells without supernatant by hand and dispersing them through a vortex machine, the cells are mixed with the cell cryopreservation solution, and a certain amount of solution is set to dispense 1.8mL of solution per cryotube. The cell suspension is dispensed into the prepared cryotubes. The dispensed cryotubes are placed in a freezing container and stored in a deep freezer. After storage in a deep freezer, the results of the intermediate judgment for the bacterial detection test are confirmed. If the result is appropriate, the cryotube is transferred to a -196°C nitrogen tank and stored until thawed.
[0154] (4) Stability test of frozen lymphocytes
[0155] 2 days after the frozen lymphocytes were transferred to -196°C nitrogen tanks, a tube of frozen lymphocytes was taken out and placed in a freezing container, and then the container was moved to a 37°C dry bath and heated to melt the lymphocytes. After suspending 0.45mL (4-fold dilution) of frozen lymphocytes dissolved in 10mL washing solution pre-dispensed in a 15mL test tube, centrifugation was performed at room temperature for 3 minutes at a rotation speed of 1,200rpm. After the supernatant of the separated cells was removed, the cells were dispersed and suspended in 10mL culture medium. After collecting the sample and transferring it to a 15mL test tube, a request was made to the quality control team to perform tests A to C. The remaining cell suspension of 2mL per well was dispensed into a 24-well plate and cultured for 2 days at 37°C, 5% CO2 in a cell culture incubator for a culture bottle. After 2 days, the cells in the culture in the 24-well plate were observed under a microscope to perform a visual inspection of the cells. After collecting the cells in the 24-well plate into a 15 mL test tube, collect a 10 μl sample during the process and then measure the number and viability of the cells to determine whether they are suitable for the test. By confirming the results of quality tests A to C in the stability test of frozen lymphocytes, determine whether they are suitable for complete cryopreservation.
[0156] A: Bacteria detection test
[0157] B: Endotoxin test
[0158] C: Mycoplasma detection test
[0159] 3. Preparation method 2
[0160] (1) Thawing and culture of lymphocytes
[0161] A tube of frozen lymphocytes was taken out, placed in a freezing container and transferred to a 37°C dry bath, then thawed. The cells dissolved in 10mL washing solution (RPMI1640 culture medium + 1.0N HCl 3mL) pre-dispensed in a test tube were suspended and centrifuged at room temperature for 3 minutes at a rotation speed of 1,200rpm. After the supernatant of the separated cells was removed, the cells were dispersed and suspended in 40mL lymphocyte culture medium. During this process, 10 μl samples were collected, the number and viability of cells were measured, and 2mL of cell suspension per well was dispensed into 24-well plates and cultured in a cell culture incubator for culture bottles at 37°C, 5% CO2.
[0162] In the case of interleukin-2, the concentration was maintained at 100 to 800 U / ml until the end of the culture.
[0163] (2) Lymphocyte culture 1
[0164] On the second day of culture, the cells in the 24-well plate were visually inspected and transferred to a T225 culture flask. Then, 50 mL of lymphocyte culture medium was added and cultured in a cell culture incubator for culture flasks at 37° C., 5% CO 2 . On the fourth day of culture, after visually inspecting the cells under a microscope, the cells in culture were dispersed and transferred to a 225 cm 2 The cells were placed in a culture flask coated with anti-CD3 antibody on the bottom area of 100 mL, and 150 mL of lymphocyte culture medium was added thereto. The cells were then cultured at 37° C. and 5% CO 2 in a cell culture incubator for culture flasks.
[0165] (3) Lymphocyte culture 2
[0166] On the 6th to 8th day of cultivation, the culture bottle is taken out to visually inspect the cells under a microscope to determine whether the cells are suitable for inspection. After this, the cells attached to the bottom are removed by patting the side of the culture bottle with hand. Collect 500 μL samples and transfer them to 15mL test tubes to count the number of cells and measure the viability (survival) of the cells. FBS is placed in the culture bottle from which the cells are taken out until the final concentration of the bag culture medium reaches 0.5%. Then, after opening the syringe port of the culture bag and disinfecting it with 70% ethanol, a 60mL lock syringe is connected to the syringe port. After using a syringe to transfer the cultured cells together with the culture medium to the culture bottle, the syringe is separated from the bag. Closed culture is carried out at 37°C, 5% CO2 in a cell culture box for the bag.
[0167] (4) Lymphocyte culture 3
[0168] After culturing in the bag for 3 to 8 days, a culture bag containing 1,000 mL of separation medium was prepared and FBS was added thereto through a syringe port until the FBS concentration reached 1%. The two lines of the culture bag and the bag containing the cells in culture were joined using a sterile connection device. After the full amount of separation medium of the culture bag was placed in the bag containing the cells in culture, the cells were evenly divided so that the same amount of the contents of the bag entered each culture container, and then the two separated bags were separately joined using a sterile adhesive. Thereafter, closed culture was performed in a cell culture incubator at 37°C, 5% CO2 for 3 days.
[0169] (5) Contamination and performance confirmation
[0170] Prior to harvesting the cells, a sample of the product in culture was taken to confirm product contamination and performance.
[0171] (5)-1: 3 days before cell collection, after visual inspection of cells, shake the culture solution before collection to mix the cells evenly. Sterilize the syringe port of the bag where cells are being cultured, then use a syringe to take 32 to 55 mL of cell culture solution and provide for requesting each test (A to C).
[0172] (5)-2: One day before or on the day of cell collection, after visual inspection of the cells, shake the culture solution before collection to mix the cells evenly. Sterilize the syringe port of the bag where the cells are being cultured, then use a syringe to take 24 to 30 mL of cell culture solution and provide it for requesting each test (D and E).
[0173] A: Sterility test
[0174] B: Mycoplasma negative test
[0175] C: Negative test for exogenous viruses
[0176] D: Confirmation test and purity test
[0177] E: Efficacy test
[0178] (6) Cell collection
[0179] The culture was terminated on the 12th to 21st day of culture, and 1,000 mL of the cell culture solution in one bag was transferred to four 250 mL test tubes. At this time, the collection line of the culture bag was sterilized with 70% ethanol and then cut with scissors.
[0180] After collecting the cells by centrifugation at a rotation speed of 2,000 rpm at room temperature for 5 minutes, the supernatant was removed and the cells were well dispersed using a vortex machine. For the remaining culture bags, the cell culture solution was collected in 4 identical test tubes, then centrifuged under the same conditions as described above, and the supernatant was removed while the cells were well dispersed.
[0181] After preparing a 0.1% human serum albumin solution by mixing human serum albumin and physiological saline, the cells in the test tube were first washed with the solution.
[0182] After the cells were collected by centrifugation at a rotation speed of 2,000 rpm at room temperature for 5 minutes, the supernatant was completely removed and the cells were dispersed using a vortex machine.
[0183] After washing the cells twice with a 0.1% human serum albumin solution, the cells were collected by centrifugation at a rotation speed of 2,000 rpm at room temperature, and then the supernatant was removed and the cells were dispersed using a vortex machine.
[0184] A 1% human serum albumin solution was prepared by mixing human serum albumin and physiological saline.
[0185] The collected cells were suspended in a 1% human serum albumin solution and then mixed uniformly. A portion of the sample was collected and provided for requesting each test (A to D).
[0186] After the line of the finished filling bag is disinfected with 70% ethanol, the line is cut and connected to a 50 mL syringe, and then the finished filling bag is filled with the cell suspension. The line of the finished filling bag is sealed 3 times (0.5 cm) at 1 cm from the inlet, and then the second sealing part is cut to finally complete the activation of lymphocytes.
[0187] A: Total cell number measurement test and cell viability test
[0188] B: Sterility test
[0189] C: Endotoxin test
[0190] D: Mycoplasma detection test
[0191] Cellular phenotype analysis of prepared activated lymphocytes
[0192] To confirm the extent of distribution of cytokine-induced killer cells, some samples of the cultured cells were collected and analyzed by fluorescence activated cell sorting (FACS).
[0193] IgG1-FITC, IgG1-PE and IgG1-APC were prepared as negative control antibodies, and anti-CD3-FITC, anti-CD8-PE, anti-CD8-FITC, anti-CD56-PE, anti-CD56 APC and anti-NKG2D-PE were prepared as experimental group antibodies (using the same antibodies with different fluorescence to prevent the overlap of fluorescence during double staining and triple staining). The buffer solution was a phosphate buffer solution containing 0.5% albumin.
[0194] The number of cells in the cultured anticancer immune cell therapy was counted, and then a cell volume of 0.5 × 10 7 After centrifugation at 1,600 rpm for 4 minutes at room temperature, the supernatant was removed and a buffer solution was added to reach 0.5×10 7 After preparing a 5 mL test tube, add 100 μL of 0.5×10 7 Each cell suspension of 10 cells / mL was added thereto, and control antibodies and experimental group antibodies were further added. After being mixed evenly, the solution was reacted at room temperature in the dark for 30 minutes. After 30 minutes, 1 mL of buffer solution was added, and then centrifuged at room temperature for 4 minutes at a rotation speed of 1,600 rpm. After removing the supernatant, 500 μl of buffer solution was added, and the cell phenotype was analyzed using a flow cytometer.
[0195] Evaluation items and evaluation methods for the anticancer efficacy of prepared activated lymphocytes, and preparation of animal models for various cancer types
[0196] 1. Identification of anticancer effects on human renal carcinoma (ACHN)
[0197] Animal model preparation and test substance administration
[0198] Nude mice were purchased and stored in a specific pathogen-free (SPF) room at the Korea Institute of Bioscience and Biotechnology and acclimatized for 1 week before use. Human renal cancer, i.e., ACHN cells, were cultured at 1.2×10 7 The concentration of 10 cells / mL was subcutaneously injected into each nude mouse. From the second day after cancer cell transplantation, the composition of the present invention was injected into the tail vein of the nude mouse once a week for a total of 4 times. As a positive control group, doxorubicin was intravenously administered at a concentration of 2 mg / kg once a week for a total of 4 times.
[0199] To observe the effects on tumor growth, tumor size, body weight and general symptoms were observed to evaluate the anticancer efficacy, and the body weight of the animals was measured to verify the toxicity to the animals.
[0200] statistics
[0201] ANOVA (Prisim, GraphPad Software, USA) and Student's t-test were used to calculate the standard deviation (SD) and p-values for all experimental results.
[0202] 2. Identification of anticancer effects on human pancreatic cancer (AsPC-1)
[0203] Animal model preparation and test substance administration
[0204] Nude mice were purchased and stored in a specific pathogen-free (SPF) room at the Korea Institute of Bioscience and Biotechnology and acclimatized for 1 week before use. Human pancreatic cancer, i.e., AsPC1 cells, were cultured at 9×10 6 The concentration of 10 cells / mL was subcutaneously injected into each nude mouse. From the second day after cancer cell transplantation, the composition of the present invention was injected into the tail vein of the nude mouse once a week for a total of 4 times. As a positive control group, doxorubicin was intravenously administered at a concentration of 2 mg / kg once a week for a total of 4 times.
[0205] To observe the effects on tumor growth, tumor size, body weight and general symptoms were observed to evaluate the anticancer efficacy, and the body weight of the animals was measured to verify the toxicity to the animals.
[0206] statistics
[0207] ANOVA (Prisim, GraphPad Software, USA) and Student's t-test were used to calculate the standard deviation (SD) and p-values for all experimental results.
[0208] 3. Identification of the anticancer effect on human melanoma cancer (LOX-IMV1)
[0209] Animal model preparation and test substance administration
[0210] Nude mice were purchased and stored in a specific pathogen-free (SPF) room at the Korea Institute of Bioscience and Biotechnology and acclimatized for 1 week before use. Human melanoma cancer, i.e., LOX-IMV1 cells, were cultured at 1.5×10 6 The concentration of 10 cells / mL was subcutaneously injected into each nude mouse. From the second day after cancer cell transplantation, the composition of the present invention was injected into the tail vein of the nude mouse once a week for a total of 3 times. As a positive control group, doxorubicin was intravenously administered at a concentration of 2 mg / kg once a week for a total of 3 times.
[0211] To observe the effects on tumor growth, tumor size, body weight and general symptoms were observed to evaluate the anticancer efficacy, and the body weight of the animals was measured to verify the toxicity to the animals.
[0212] statistics
[0213] ANOVA (Prisim, GraphPad Software, USA) and Student's t-test were used to calculate the standard deviation (SD) and p-values for all experimental results.
[0214] 4. Identification of anticancer effects on human prostate cancer (PC-3)
[0215] Animal model preparation and test substance administration
[0216] Nude mice were purchased and stored in a specific pathogen-free (SPF) room at the Korea Institute of Bioscience and Biotechnology and acclimatized for 1 week before use. Human prostate cancer, i.e., PC-3 cells, were cultured at 9×10 6 The concentration of 10 cells / mL was subcutaneously injected into each nude mouse. From the second day after cancer cell transplantation, the composition of the present invention was injected into the tail vein of the nude mouse once a week for a total of 4 times. As a positive control group, doxorubicin was intravenously administered at a concentration of 2 mg / kg once a week for a total of 4 times.
[0217] To observe the effects on tumor growth, tumor size, body weight and general symptoms were observed to evaluate the anticancer efficacy, and the body weight of the animals was measured to verify the toxicity to the animals.
[0218] statistics
[0219] ANOVA (Prisim, GraphPad Software, USA) and Student's t-test were used to calculate the standard deviation (SD) and p-values for all experimental results.
[0220] 5. Identification of anticancer effects on human colon cancer (SW620)
[0221] Animal model preparation and test substance administration
[0222] Nude mice were purchased and stored in a specific pathogen-free (SPF) room at the Korea Institute of Bioscience and Biotechnology and acclimatized for 1 week before use. Human colon cancer, i.e., SW620 cells, were cultured at 6×10 6 The concentration of 10 cells / mL was subcutaneously injected into each nude mouse. From the second day after cancer cell transplantation, the composition of the present invention was injected into the tail vein of the nude mouse once a week for a total of 4 times. As a positive control group, doxorubicin was intravenously administered at a concentration of 2 mg / kg once a week for a total of 4 times.
[0223] To observe the effects on tumor growth, tumor size, body weight and general symptoms were observed to evaluate the anticancer efficacy, and the body weight of the animals was measured to verify the toxicity to the animals.
[0224] statistics
[0225] ANOVA (Prisim, GraphPad Software, USA) and Student's t-test were used to calculate the standard deviation (SD) and p-values for all experimental results.
[0226] Results of cell phenotype analysis of activated lymphocytes
[0227] 1) As a result of analyzing the cell phenotype of the cytokine-induced killer cells prepared according to the above example, CD56 + Cells account for 46.9% of the total cells. Among them, CD3 + CD56 + Cell populations (independent of MHC and compared to those expressing only CD56 + The cell population has a higher proliferation rate and cytotoxic activity) accounted for 44.4%, and then accounted for CD56 + 94.7% of cells co-expressed CD8 + CD56 + The cell population co-expressing CD3 + CD8 + The cytotoxic T lymphocytes were 65% (see Figure 1 ).
[0228] 2) As a method for treating CD8 + The activated lymphocytes prepared in the above example were gated to analyze CD8 + CD56 + The results of expression of CD8 + CD56 + NKG2D + The cells account for 28% of all cells.
[0229] Results of evaluation of the anticancer effect of the prepared activated lymphocytes
[0230] 1. Evaluation results of anticancer effect on human renal carcinoma (ACHN)
[0231] 1) Changes in tumor size
[0232] In the case of the control group, the cells were allowed to grow to a size of 321 ± 47 mm on day 28. 3 , and when 1×10 6 When the composition of the present invention is administered to 10 cells / mouse, the size is 274±51 mm 3 , indicating a 14% growth inhibition. On the other hand, when 3×10 6 When the composition of the present invention is administered to 10 cells / mouse, the size is 209±26 mm 3, indicating a 34% growth inhibition (p<0.05). 6 When the composition of the present invention is administered to cells / mouse, the size is 138±32 mm 3 , indicating 56% growth inhibition (p<0.01). In the doxorubicin-administered group used as a positive control group, the size was 192±44 mm 3 , indicating 40% cancer growth inhibition.
[0233] 2) Changes in tumor weight
[0234] After the tumors were isolated on the last day (day 28), the weight was measured. In the case of the control group, the average tumor weight was 651±164 mg, and when 1×10 6 When the composition of the present invention was administered at 1×10 cells / mouse, the tumor weight was 530±100 mg, indicating 18% growth inhibition. 6 When the composition was administered at 10×10 6 When the composition of the present invention was administered to 10 cells / mouse, the tumor weight was 308±95 mg, indicating 52% growth inhibition (p<0.01). In the doxorubicin administration group used as a positive control group, the tumor weight was 409±41 mg, indicating 37% cancer growth inhibition (p<0.05).
[0235] 3) Changes in weight
[0236] Compared with the body weight (100%) on day 1, on day 28, the control group showed a body weight change of 105%, while the group administered with the composition of the present invention showed a body weight change of 104% to 106%. In addition, the doxorubicin administration group showed a normal body weight change of 95%. In addition, no abnormal behavior was observed.
[0237] 4) Observation of general symptoms
[0238] During the 28-day period of administration of the composition of the present invention, no dead animals were observed, and no animals with abnormal behaviors were observed.
[0239] 2. Identification of anticancer effects on human pancreatic cancer (AsPC-1)
[0240] 1) Changes in tumor size
[0241] In the case of the control group, the tumor grew to 251 ± 50 mm on day 25. 3 , and when 1×10 6 When the composition of the present invention is administered to cells / mouse, the size is 192±25 mm3 , indicating a 23% growth inhibition (p<0.05). 6 When the composition of the present invention is administered to cells / mouse, the size is 146±26 mm 3 , indicating a 42% growth inhibition (p<0.01). 6 When the composition of the present invention is administered to cells / mouse, the size is 73±30 mm 3 , indicating 70% growth inhibition (p<0.01). In the doxorubicin-administered group used as a positive control group, the size was 130±28 mm 3 , indicating 48% cancer growth inhibition.
[0242] 2) Changes in tumor weight
[0243] After the tumors were isolated on the last day (day 25), the weight was measured. In the case of the control group, the average tumor weight was 790 ± 193 mg, and when 1 × 10 6 When the composition of the present invention was administered at 1×10 cells / mouse, the tumor weight was 591±106 mg, indicating a 25% growth inhibition (p<0.05). 6 When the composition was administered at 10×10 6 When the composition of the present invention was administered to 10 cells / mouse, the tumor weight was 267±84 mg, indicating 66% growth inhibition (p<0.01). In the doxorubicin administration group used as a positive control group, the tumor weight was 473±64 mg, indicating 44% cancer growth inhibition (p<0.01).
[0244] 3) Changes in weight
[0245] Compared with the body weight (100%) on day 1, on day 25, the control group showed a body weight change of 130%, while the group administered with the composition of the present invention showed a body weight change of 120% to 125%. In addition, the doxorubicin administration group showed a normal body weight change of 125%. In addition, no abnormal behavior was observed.
[0246] 4) Observation of general symptoms
[0247] During the 25-day period of administration of the composition of the present invention, no dead animals were observed, and no animals with abnormal behaviors were observed.
[0248] 3. Identification of the anticancer effect on human melanoma cancer (LOX-IMV1)
[0249] 1) Changes in tumor size
[0250] In the case of the control group, the tumor grew to 254 ± 43 mm on day 15. 3 , and when 1×10 6 When the composition of the present invention is administered to cells / mouse, the size is 167±78 mm 3 , indicating a 34% growth inhibition (p<0.05). 6 When the composition of the present invention is administered to cells / mouse, the size is 108±35 mm 3 , indicating a 57% growth inhibition (p<0.01). 6 When the composition of the present invention is administered to cells / mouse, the size is 60±21 mm 3 , indicating 76% growth inhibition (p<0.01). In the doxorubicin-administered group used as a positive control group, the size was 71±458 mm 3 , indicating 72% cancer growth inhibition.
[0251] 2) Changes in tumor weight
[0252] After the tumors were isolated on the last day (day 15), the weight was measured. In the case of the control group, the average tumor weight was 1676±530 mg, and when 1×10 6 When the composition of the present invention was administered at 1×10 cells / mouse, the tumor weight was 1158±631 mg, indicating a 30% growth inhibition (p<0.05). 6 When the composition was administered at 10×10 6 When the composition of the present invention was administered to 10 cells / mouse, the tumor weight was 401±166 mg, indicating 76% growth inhibition (p<0.01). In the doxorubicin administration group used as a positive control group, the tumor weight was 496±306 mg, indicating 70% cancer growth inhibition (p<0.01).
[0253] 3) Changes in weight
[0254] Compared to the body weight (100%) on day 1, on day 15, the control group showed a body weight change of 130%, while the group administered with the composition of the present invention showed a body weight change of 121% to 126%. In addition, the doxorubicin administration group showed a normal body weight change of 122%. In addition, no abnormal behavior was observed.
[0255] 4) Observation of general symptoms
[0256] During the 15-day period of administration of the composition of the present invention, no dead animals were observed, and no animals with abnormal behaviors were observed.
[0257] 4. Identification of anticancer effects on human prostate cancer (PC-3)
[0258] 1) Changes in tumor size
[0259] In the case of the control group, the tumor grew to 378 ± 23 mm on day 22. 3 , and when 1×10 6 When the composition of the present invention is administered to 10 cells / mouse, the size is 300±54 mm 3 , indicating 20% growth inhibition (p<0.01). 6 When the composition of the present invention is administered to cells / mouse, the size is 211±33 mm 3 , indicating a 44% growth inhibition (p<0.01). 6 When the composition of the present invention is administered to cells / mouse, the size is 183±22 mm 3 , indicating 51% growth inhibition (p<0.01). In the doxorubicin-administered group used as a positive control group, the size was 225±59 mm 3 , indicating 40% cancer growth inhibition.
[0260] 2) Changes in tumor weight
[0261] After the tumors were isolated on the last day (day 22), the weight was measured. In the case of the control group, the average tumor weight was 1346±159 mg, and when 1×10 6 When the composition of the present invention was administered at 1×10 cells / mouse, the tumor weight was 1018±127 mg, indicating a 24% growth inhibition (p<0.01). 6 When the composition was administered at 10×10 6 When the composition of the present invention was administered to 10 cells / mouse, the tumor weight was 677±56 mg, indicating 49% growth inhibition (p<0.01). In the doxorubicin administration group used as a positive control group, the tumor weight was 808±156 mg, indicating 40% cancer growth inhibition (p<0.01).
[0262] 3) Changes in weight
[0263] Compared with the body weight (100%) on day 1, on day 22, the control group showed a body weight change of 103%, while the group administered with the composition of the present invention showed a body weight change of 103% to 106%. In addition, the doxorubicin administration group showed a normal body weight change of 102%. In addition, no abnormal behavior was observed.
[0264] 4) Observation of general symptoms
[0265] During the 22-day period of administration of the composition of the present invention, no dead animals were observed, and no animals with abnormal behaviors were observed.
[0266] 5. Identification of anticancer effects on human colon cancer (SW620)
[0267] 1) Changes in tumor size
[0268] In the case of the control group, the tumor grew to 473 ± 190 mm on day 25. 3 , and when 1×10 6 When the composition of the present invention is administered to 10 cells / mouse, the size is 436±214 mm 3 , indicating 7% growth inhibition (not significant). On the other hand, when 3×10 6 When the composition of the present invention is administered to cells / mouse, the size is 220±138 mm 3 , indicating a 53% growth inhibition (p<0.05). 6 When the composition of the present invention is administered to cells / mouse, the size is 127±60 mm 3 , indicating 73% growth inhibition (p<0.01). In the doxorubicin-administered group used as a positive control group, the size was 142±97 mm 3 , indicating 48% cancer growth inhibition (p<0.05).
[0269] 2) Changes in tumor weight
[0270] After the tumors were isolated on the last day (day 25), the weight was measured. In the case of the control group, the average tumor weight was 1661±817 mg, and when 1×10 6 When the composition of the present invention was administered at 1×10 cells / mouse, the tumor weight was 1482±659 mg, indicating a 10% growth inhibition (not significant). 6 When the composition was administered at 10×10 6When the composition of the present invention was administered to 10 cells / mouse, the tumor weight was 440±222 mg, indicating 73% growth inhibition (p<0.001). In the doxorubicin administration group used as a positive control group, the tumor weight was 834±306 mg, indicating 49% cancer growth inhibition (p<0.05).
[0271] 3) Changes in weight
[0272] Compared to the body weight (100%) on day 1, on day 25, the control group showed a body weight change of 116%, while the group administered with the composition of the present invention showed a body weight change of 120% to 121%. In addition, the doxorubicin-administered group showed a normal body weight change of 114%. In addition, no abnormal behavior was observed.
[0273] 4) Observation of general symptoms
[0274] During the 25-day period of administration of the composition of the present invention, no dead animals were observed, and no animals with abnormal behaviors were observed.
[0275] [Table 1]
[0276]
[0277] a: Number of human cancer cells administered to nude mice
[0278] b: Tumor weight measurement and the last day of the experiment
[0279] c: Tumor growth rate of the control group (%)
[0280] d: Administration of anticancer immune cell therapy composition (1×10 6 The tumor growth rate (%) of the group with 40 cells / mouse compared with the control group
[0281] e: Administration of anticancer immune cell therapy composition (3×10 6 The tumor growth rate (%) of the group with 40 cells / mouse compared with the control group
[0282] f: Administration of anticancer immune cell therapy composition (10×10 6 The tumor growth rate (%) of the group with 40 cells / mouse compared with the control group
[0283] g: Tumor growth rate (%) of the group given doxorubicin (2 mg / kg) compared with the control group
[0284] Domestic clinical trials of activated lymphocytes
[0285] 1. Liver cancer clinical trials
[0286] According to the AJCC staging method for liver cancer (6th edition), the safety and efficacy of the composition of the present invention were evaluated in 230 patients who received radical treatment (surgical resection, radiofrequency heat therapy or percutaneous ethanol infusion) for stage I or II hepatocellular carcinoma. The median recurrence-free survival (RFS) was 44 months in the immunotherapy group and 30 months in the control group (p = 0.010), demonstrating a statistically significant difference, HR0.63 (95% CI, 0.43-0.94). As a secondary outcome variable, the overall survival in the immunotherapy group was longer than that in the control group, HR0.21 (95% CI, 0.06-0.75; p = 0.008).
[0287] 2. Long-term follow-up of clinical trials for liver cancer
[0288] Among the patients who participated in the clinical trial, those who signed and agreed to long-term follow-up were followed up for long-term survival at intervals of up to 6 months from the end of the clinical trial for up to 36 months. The relapse-free survival rate at 60 months was 44.8% in the immunotherapy group and 33.1% in the control group, demonstrating a statistically significant difference (p=0.0033).
[0289] 3. Clinical trials for malignant glioma
[0290] For patients with malignant glioma, the effectiveness of the composition of the present invention was evaluated. The median of progression-free survival (PFS) was 8.1 months (95% confidence interval (CI), 5.8 to 8.5 months) in the immunotherapy group and 5.4 months (95% CI, 3.3 to 7.9 months, p = 0.0401) in the control group. The median of overall survival was 22.5 months (95% CI, 17.2 to 23.9 months) in the immunotherapy group and 16.9 months (95% CI, 13.9 to 21.9 months) in the control group, and there was no statistically significant difference. However, it was extended by 5.6 months in the immunotherapy group.
[0291] 4. Pancreatic cancer clinical trials
[0292] The effectiveness of the composition of the present invention was evaluated for patients with pancreatic cancer. The median value of disease-free survival was 11.0 weeks (95% CI, 8.8 to 13.2 weeks), and the median value of overall survival was 26.6 weeks (95% CI, 8.6 to 44.6 weeks). The 6-month survival rate from the date of registration was 60%.
Claims
1. A composition for preparing a cell line containing 20% or more CD8 + CD56 + NKG2D + The activated lymphocytes of cells, the composition comprising: The culture medium in the first culture step comprises 1-10 μg / ml of anti-CD3 antibody, 500-800 U / ml of interleukin-2 and 8-12% by volume of FBS; The culture medium in the second culture step contains 100-300 U / ml interleukin-2 and 0.3-0.8 volume % FBS, but does not contain anti-CD3 antibody; and The culture medium in the third culture step contains 100-300 U / ml interleukin-2 and 0.5-1.5 volume % FBS, but does not contain anti-CD3 antibody, The culture medium in the first culture step, the culture medium in the second culture step, and the culture medium in the third culture step do not contain IFN-γ (interferon-γ).
